{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-293485","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2026-07-02T12:00:40+00:00","discovered_at":"2026-07-02T12:05:00.543815+00:00","generated_at":"2026-07-02T12:05:06.398338+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tenax Therapeutics to present Phase 3 LEVEL trial results at ESC Congress 2026; topline data expected in August","bullets":["Phase 3 LEVEL trial results to be presented in Late-Breaking Clinical Science session at ESC Congress 2026 (Aug 28-31, Munich).","Company expects to report topline data in August 2026; database lock and statistical analysis underway.","Trial evaluates TNX-103 (oral levosimendan) in PH-HFpEF; enrollment of >230 patients completed March 2026.","BSSR in Dec 2025 showed >90% power to detect 25m change in 6MWD primary endpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-293485","json":"https://secwatch.observer/filing/0001193125-26-293485.json","markdown":"https://secwatch.observer/filing/0001193125-26-293485.md","text":"https://secwatch.observer/filing/0001193125-26-293485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000119312526293485/0001193125-26-293485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000119312526293485/d20457d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-02T12:05:06.398338+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}